Yes (strong) FDA status FDA-approved (T2D and obesity) Compound NAD+ (intravenous or subcutaneous) Mechanism Direct NAD+ supplementation Route IV infusion or subcutaneous Acts on appetite
Our experience shows that researchers often begin with a lower concentration, such as 1-2 M, and then gradually increase it to observe dose-dependent effects
Research demonstrates a 70% increase in peak torque and a significant acceleration in healing following muscle injury in aged subjects
AOD-9604 produces fat loss without any IGF-1 elevation, preserves normal glucose metabolism and insulin sensitivity, does not promote muscle growth or tissue proliferation, shows minimal fluid retention or edema, and requires less intensive monitoring due to absence of systemic effects
Research indicates that it helps in the brain and mood
With 476,857 individuals across 18 different countries (propensity score matched 1:1 with pregnant controls), this is the largest study to date in this historically underserved population
